Skip to main content
Changchun Bcht Biotechnology Co. logo

Changchun Bcht Biotechnology Co. — Investor Relations & Filings

Ticker · 688276 ISIN · CNE100005XY6 LEI · 8368000E14LIZR0C4328 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2024-03-12 Investor Presentation
Country CN China
Listing Shanghai Stock Exchange 688276

About Changchun Bcht Biotechnology Co.

http://www.bchtpharm.com

Changchun BCHT Biotechnology Co. is a biopharmaceutical enterprise focused on the research, development, production, and marketing of human vaccines. The company specializes in preventing infectious diseases through innovative biological products. Its primary product portfolio includes the Varicella Vaccine (Live), which maintains a significant market presence, and the Influenza Vaccine (Live, Nasal, Freeze-dried). Additionally, the company produces the Rabies Vaccine for human use and has expanded its pipeline to include a Herpes Zoster vaccine. BCHT Biotechnology emphasizes technological innovation, utilizing advanced platforms for viral culture and purification to ensure product safety and efficacy. The company operates large-scale manufacturing facilities designed to meet international quality standards, aiming to address public health needs through a diverse range of immunization solutions.

Recent filings

Filing Released Lang Actions
长春百克生物科技股份公司关于召开2023年度业绩说明会的公告
Investor Presentation Classification · 90% confidence The document is an announcement about the scheduling and details of a 2023 annual performance briefing (业绩说明会) to be held on March 20, 2024. It mentions that the company will release its 2023 annual report on the same day, but this document itself is not the annual report or the earnings release. It is a notice informing investors about the upcoming event where management will discuss the annual results and answer questions. The document is relatively short (1423 characters) and serves as an invitation and information about the investor meeting rather than containing financial data or results. Therefore, it fits the category of an Investor Presentation announcement or briefing notice. However, since it is specifically about an earnings performance explanation meeting rather than a full presentation document, and given the options, the best fit is Investor Presentation (IP).
2024-03-12 Chinese
长春百克生物科技股份公司2023年度业绩快报公告
Earnings Release Classification · 95% confidence The document is titled as a "2023年度业绩快报公告" which translates to "2023 Annual Performance Express Report Announcement." It contains preliminary financial data for the full year 2023, including revenue, profit, net profit, earnings per share, and asset figures. The data is explicitly stated as preliminary and unaudited, with a disclaimer that the final audited figures will be in the company's 2023 Annual Report. The document is relatively short (1856 characters) and serves as a quick earnings update rather than a full comprehensive report. It does not contain detailed financial statements or extensive analysis typical of an Annual Report (10-K) or Interim Report (IR). It is also not a full Earnings Release (ER) since it covers the full year and is preliminary. This type of document is best classified as an Earnings Release (ER) because it announces key financial results for the year but is not the full annual report itself. FY 2023
2024-02-23 Chinese
长春百克生物科技股份公司第五届监事会第十六次会议决议的公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of a supervisory board meeting resolution regarding the approval of an asset impairment provision for the year 2023. It includes details about the meeting date, attendance, voting results, and compliance with accounting standards. The document references another announcement (2024-003) for detailed content. The document is short (703 characters) and serves as a meeting resolution announcement rather than a full financial report or audit report. It does not contain full financial statements or detailed audit information, nor is it a regulatory certification or voting result announcement. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2024-02-23 Chinese
长春百克生物科技股份公司关于2023年度计提资产减值准备的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by the board of directors regarding the company's decision to make an asset impairment provision for the fiscal year 2023. It details the amount of impairment, the rationale behind it, and the impact on the company's financials. The document is relatively short (1776 characters) and focuses on a specific accounting decision rather than presenting comprehensive financial statements or a full audit report. It does not contain full financial data or detailed financial analysis typical of an Annual Report (10-K) or Interim Report (IR). Instead, it is a regulatory announcement about a specific accounting provision. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such announcements that do not fit other specific categories.
2024-02-23 Chinese
长春百克生物科技股份公司2023年年度业绩预告的公告
Earnings Release Classification · 95% confidence The document is an announcement of the company's 2023 annual performance forecast, including estimated net profit and revenue figures for the year ending December 31, 2023. It explicitly states that the financial data are preliminary and unaudited, and that the final accurate financial data will be disclosed in the formal 2023 annual report. The document length is short (1098 characters) and it serves as a performance forecast announcement rather than a full annual report containing detailed financial statements. Therefore, it is best classified as an Earnings Release (ER), which covers initial announcements of periodic financial results or forecasts. FY 2023
2024-01-15 Chinese
长春百克生物科技股份公司2023年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled as a resolution announcement from the company's first extraordinary general meeting of shareholders in 2023. It details the meeting date, attendance, voting results on various proposals, and legal witness statements. There is no financial data or report content, only the official voting results and procedural compliance information. This matches the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short and focused on voting outcomes, not a full report or presentation.
2023-12-29 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.